BGBIO.OL

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$1M	+17.5%	$-0.04	$-0.04–$-0.04	—	1
2027	$1M	+17.5%	$-0.04	$-0.04–$-0.04	—	1
2028	$19M	+1259.0%	$-6.50	$-6.50–$-6.50	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 7 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2025-08-20	$-9.06	$-1.38	+84.8%
2025-02-26	$-1.09	$-1.09	+0.0%
2024-11-13	$-1.34	$-0.63	+53.0%
2024-05-23	$-2.00	$-1.00	+50.0%
2023-11-14	$-0.02	$-0.01	+50.0%
2023-02-16	$-0.85	$-0.87	-2.4%
2022-11-15	$-0.82	$-0.67	+18.3%
2022-05-24	$-0.81	$-0.78	+3.7%

DCF fair valuemodel estimate

Intrinsic value

$3.59

Price

$1.17

Implied upside

+207%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
BGBIO.OLBerGenBio ASA	$1.17	+0.00%	$46M	—
IDEX.OLIDEX Biometrics ASA	$5.62	-6.33%	$434M	—
LYTIX.OLLytix Biopharma AS	$8.50	+0.00%	$654M	—
PCIB.OLPCI Biotech Holding ASA	$0.07	+0.00%	$3M	—
PHO.OLPhotocure ASA	$51.70	+1.17%

BerGenBio ASA

BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.

www.bergenbio.com

Employees: 13
IPO / List date: Apr 7, 2017
HQ: NO

Held by traders on TradeandTell

No one on the platform currently holds BGBIO.OL.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in BGBIO.OL as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded BGBIO.OL yet.